Michele Battaglia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3570110/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies. Urologia Internationalis, 2022, 106, 75-82.	0.6	4
2	Novel Insights into Autophagy and Prostate Cancer: A Comprehensive Review. International Journal of Molecular Sciences, 2022, 23, 3826.	1.8	31
3	Pre-Transplant Expression of CCR-2 in Kidney Transplant Recipients Is Associated With the Development of Delayed Graft Function. Frontiers in Immunology, 2022, 13, 804762.	2.2	3
4	Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer. International Journal of Molecular Sciences, 2022, 23, 4173.	1.8	40
5	Robotic-assisted Partial Nephrectomy for "Very Small―(<2 cm) Renal Mass: Results of a Multicenter Contemporary Cohort. European Urology Focus, 2021, 7, 1115-1120.	1.6	7
6	DelCFHR3â€1 influences graft survival in transplant patients with IgA nephropathy via complementâ€mediated cellular senescence. American Journal of Transplantation, 2021, 21, 838-845.	2.6	8
7	Outcomes of robot-assisted partial nephrectomy for completely endophytic renal tumors: A multicenter analysis. European Journal of Surgical Oncology, 2021, 47, 1179-1186.	0.5	32
8	Robotic radical perineal prostatectomy: tradition and evolution in the robotic era. Current Opinion in Urology, 2021, 31, 11-17.	0.9	10
9	Pentraxin-3-mediated complement activation in a swine model of renal ischemia/reperfusion injury. Aging, 2021, 13, 10920-10933.	1.4	9
10	Robot-assisted radical prostatectomy versus standard laparoscopic radical prostatectomy: an evidence-based analysis of comparative outcomes. World Journal of Urology, 2021, 39, 3721-3732.	1.2	37
11	Novel Insights into the Molecular Mechanisms of Ischemia/Reperfusion Injury in Kidney Transplantation. Transplantology, 2021, 2, 191-207.	0.3	4
12	Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. Frontiers in Oncology, 2021, 11, 651745.	1.3	11
13	A risk-group classification model in patients withÂbladder cancerÂunder neoadjuvant cisplatin-based combination chemotherapy. Future Oncology, 2021, 17, 3987-3994.	1.1	3
14	Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy. Future Science OA, 2021, 7, FSO709.	0.9	40
15	CD40 Cross-Linking Induces Migration of Renal Tumor Cell through Nuclear Factor of Activated T Cells (NFAT) Activation. International Journal of Molecular Sciences, 2021, 22, 8871.	1.8	3
16	The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: the perspective through bibliometric analysis of an Italian translational working group in uro-oncology. Minerva Urology and Nephrology, 2021, 73, 442-451.	1.3	23
17	Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. Translational Andrology and Urology, 2021, 10, 626-635.	0.6	20
18	Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicentre study. Minerva Urology and Nephrology, 2021, , .	1.3	3

MICHELE BATTAGLIA

#	Article	IF	CITATIONS
19	Circulating preoperative testosterone level predicts unfavourable disease at radical prostatectomy in men with International Society of Urological Pathology Grade Group 1 prostate cancer diagnosed with systematic biopsies. World Journal of Urology, 2020, 39, 1861-1867.	1.2	14
20	An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas. Expert Opinion on Pharmacotherapy, 2020, 21, 2199-2204.	0.9	3
21	Integration of Lipidomics and Transcriptomics Reveals Reprogramming of the Lipid Metabolism and Composition in Clear Cell Renal Cell Carcinoma. Metabolites, 2020, 10, 509.	1.3	51
22	Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 459-464.	0.8	42
23	Management of severe complications following penile surgery for erectile dysfunction and Peyronie disease. Medicine (United States), 2020, 99, e18690.	0.4	1
24	PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma. Aging, 2020, 12, 7585-7602.	1.4	78
25	Interleukin-27 is a potential marker for the onset of post-transplant malignancies. Nephrology Dialysis Transplantation, 2019, 34, 157-166.	0.4	9
26	An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World Journal of Urology, 2019, 37, 507-514.	1.2	77
27	Renal progenitor cells revert LPSâ€induced endothelialâ€toâ€mesenchymal transition by secreting CXCL6, SAA4, and BPIFA2 antiseptic peptides. FASEB Journal, 2019, 33, 10753-10766.	0.2	35
28	Recurrent urinary tract infections in kidney transplant recipients during the first-year influence long-term graft function: a single-center retrospective cohort study. Journal of Nephrology, 2019, 32, 661-668.	0.9	25
29	Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Review of Molecular Diagnostics, 2019, 19, 397-407.	1.5	133
30	Adherence to the EAU guidelines on Penile Cancer Treatment: European, multicentre, retrospective study. Journal of Cancer Research and Clinical Oncology, 2019, 145, 921-926.	1.2	18
31	Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update. Expert Review of Molecular Diagnostics, 2019, 19, 377-387.	1.5	43
32	Penile prosthesis implant for primary erectile dysfunction in patient with Klippel-Trenaunay syndrome complicated by consumptive coagulopathy. Medicine (United States), 2019, 98, e16741.	0.4	3
33	Adherence to EAU guidelines on penile cancer translates into better outcomes: a multicenter international study. World Journal of Urology, 2019, 37, 1649-1657.	1.2	27
34	Complement component C5a induces aberrant epigenetic modifications in renal tubular epithelial cells accelerating senescence by Wnt4/βcatenin signaling after ischemia/reperfusion injury. Aging, 2019, 11, 4382-4406.	1.4	66
35	Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. Aging, 2018, 10, 3957-3985.	1.4	133
36	FP693RENAL ACUTE AND CHRONIC ANTIBODY-MEDIATED REJECTION (AMR) ACCELERATE THE TUBULAR SENESCENCE INCREASING THE EXPRESSION OF CELL CYCLE NEGATIVE REGULATORS. Nephrology Dialysis Transplantation, 2018, 33, i279-i280.	0.4	0

MICHELE BATTAGLIA

#	Article	IF	CITATIONS
37	High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study. Urologia Internationalis, 2018, 101, 7-15.	0.6	22
38	Complement Activation During Ischemia/Reperfusion Injury Induces Pericyte-to-Myofibroblast Transdifferentiation Regulating Peritubular Capillary Lumen Reduction Through pERK Signaling. Frontiers in Immunology, 2018, 9, 1002.	2.2	47
39	Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non–muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 445-452.	0.9	55
40	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget, 2018, 9, 19861-19873.	0.8	37
41	Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell car carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 461.e15-461.e27.	0.8	75
42	The emerging role of obesity, diet and lipid metabolism in prostate cancer. Future Oncology, 2017, 13, 285-293.	1.1	55
43	Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance. Oncotarget, 2017, 8, 18424-18434.	0.8	52
44	Urinary RKIP/p-RKIP is a potential diagnostic and prognostic marker of clear cell renal cell carcinoma. Oncotarget, 2017, 8, 40412-40424.	0.8	50
45	Renal Cell Carcinoma: A Study through NMR-Based Metabolomics Combined with Transcriptomics. Diseases (Basel, Switzerland), 2016, 4, 7.	1.0	62
46	The Three-Gene Signature in Urinary Extracellular Vesicles from Patients with Clear Cell Renal Cell Carcinoma. Journal of Cancer, 2016, 7, 1960-1967.	1.2	41
47	Multi-omics approach reveals the secrets of metabolism of clear cell—renal cell carcinoma. Translational Andrology and Urology, 2016, 5, 801-803.	0.6	14
48	Urological Infections Due to Multidrug-Resistant Bacteria: What We Need to Know?. Urologia, 2016, 83, 21-26.	0.3	3
49	miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction. Journal of Translational Medicine, 2016, 14, 84.	1.8	34
50	Establishment and characterization of a highly immunogenic human renal carcinoma cell line. International Journal of Oncology, 2016, 49, 457-470.	1.4	3
51	The Role of Renal Surgery in the Era of Targeted Therapy: The Urologist's Perspective. Urologia, 2015, 82, 137-138.	0.3	27
52	Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget, 2015, 6, 13371-13386.	0.8	138
53	Soluble Serum αKlotho Is a Potential Predictive Marker of Disease Progression in Clear Cell Renal Cell Carcinoma. Medicine (United States), 2015, 94, e1917.	0.4	48
54	Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell–Renal Cell Carcinoma. Medicine (United States), 2015, 94, e2117.	0.4	45

MICHELE BATTAGLIA

#	Article	IF	CITATIONS
55	Isolation and Characterization of Cancer Stem Cells in Renal Cell Carcinoma. Urologia, 2015, 82, 46-53.	0.3	14
56	Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer. Expert Review of Molecular Diagnostics, 2015, 15, 1211-1224.	1.5	57
57	Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38. Autophagy, 2015, 11, 2102-2113.	4.3	27
58	Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospective study with RCC diagnosed in the general population. World Journal of Urology, 2015, 33, 1-7.	1.2	51
59	Emerging Urinary Markers of Renal Injury in Obstructive Nephropathy. BioMed Research International, 2014, 2014, 1-7.	0.9	58
60	Diagnostic and Prognostic Role of Preoperative Circulating CA 15-3, CA 125, and Beta-2 Microglobulin in Renal Cell Carcinoma. Disease Markers, 2014, 2014, 1-9.	0.6	47
61	Endothelial-to-mesenchymal transition and renal fibrosis in ischaemia/reperfusion injury are mediated by complement anaphylatoxins and Akt pathway. Nephrology Dialysis Transplantation, 2014, 29, 799-808.	0.4	98
62	CTR2 Identifies a Population of Cancer Cells with Stem Cell-like Features in Patients with Clear Cell Renal Cell Carcinoma. Journal of Urology, 2014, 192, 1831-1841.	0.2	35
63	Pre-existing Type 2 Diabetes Mellitus Is an Independent Risk Factor for Mortality and Progression in Patients With Renal Cell Carcinoma. Medicine (United States), 2014, 93, e183.	0.4	45
64	Delayed Relief of Ureteral Obstruction is Implicated in the Long-Term Development of Renal Damage and Arterial Hypertension in Patients with Unilateral Ureteral Injury. Journal of Urology, 2013, 189, 960-965.	0.2	61
65	JAK3 in clear cell renal cell carcinoma: Mutational screening and clinical implications. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 930-937.	0.8	23
66	Spondin-2, a Secreted Extracellular Matrix Protein, is a Novel Diagnostic Biomarker for Prostate Cancer. Journal of Urology, 2013, 190, 2271-2277.	0.2	67
67	Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer. Future Oncology, 2013, 9, 899-907.	1.1	35
68	VHL Gene Alterations in Italian Patients with Isolated Renal Cell Carcinomas. International Journal of Biological Markers, 2013, 28, 208-215.	0.7	3
69	Genome-Wide Analysis of Differentially Expressed Genes and Splicing Isoforms in Clear Cell Renal Cell Carcinoma. PLoS ONE, 2013, 8, e78452.	1.1	19
70	Regulation of TGF-β1 expression by Androgen Deprivation Therapy of prostate cancer. Cancer Letters, 2012, 318, 135-144.	3.2	20
71	Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. Prostate, 2012, 72, 1611-1621.	1.2	83
72	Androgen deprivation therapy affects BCL-2 expression in human prostate cancer. International Journal of Oncology, 2011, 39, 1233-42.	1.4	11

#	Article	IF	CITATIONS
73	Patient and Partner Satisfaction after AMS Inflatable Penile Prosthesis Implant. Journal of Sexual Medicine, 2010, 7, 304-309.	0.3	84
74	Transperitoneal Deviceless Hand-Assisted Laparoscopic Living Donor Nephrectomy: An Alternative Technique for Kidney Recovery. Journal of Endourology, 2010, 24, 1617-1623.	1.1	5
75	JAK3/STAT5/6 Pathway Alterations Are Associated with Immune Deviation in <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"> <mml:mrow> <mml:mtext>CD </mml:mtext> <mml:msup> < mathvariant="bold">8 <mml:mtext> + </mml:mtext> </mml:msup> </mml:mrow> </mml:math> T Cells in Renal Cell Carcinoma Patients. Iournal of Biomedicine and Biotechnology. 2010. 2010. 1-13.	mml:mn	22
76	Therapeutic Targeting of Classical and Lectin Pathways of Complement Protects from Ischemia-Reperfusion-Induced Renal Damage. American Journal of Pathology, 2010, 176, 1648-1659.	1.9	136
77	Penile prostheses. Therapeutic Advances in Urology, 2010, 2, 35-40.	0.9	33
78	Unusual solitary metastasis of the ciliary body in renal cell carcinoma. International Journal of Urology, 2008, 15, 363-365.	0.5	12
79	Increase of Proliferating Renal Progenitor Cells in Acute Tubular Necrosis Underlying Delayed Graft Function. Transplantation, 2008, 85, 1112-1119.	0.5	50
80	Interferon-alpha (IFN-α)–conditioned DC Preferentially Stimulate Type-1 and Limit Treg-type In Vitro T-cell Responses From RCC Patients. Journal of Immunotherapy, 2008, 31, 254-262.	1.2	43
81	Testicular granulosa cell tumor of adult type: A new case and a review of the literature. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 322-325.	0.8	23
82	Lethal somatostatin analog-induced acute necrotizing pancreatitis in a patient with hormone-refractory prostate cancer. Scandinavian Journal of Urology and Nephrology, 2006, 40, 423-425.	1.4	7
83	Bilateral tumors of the testis in 21-alpha hydroxylase deficiency without adrenal hyperplasia. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 178-180.	0.8	12
84	Ischemia-Reperfusion Induces Glomerular and Tubular Activation of Proinflammatory and Antiapoptotic Pathways: Differential Modulation by Rapamycin. Journal of the American Society of Nephrology: JASN, 2004, 15, 2675-2686.	3.0	91
85	Prospective randomized trial comparing high lumbotomic with laparotomic access in renal cell carcinoma surgery. Scandinavian Journal of Urology and Nephrology, 2004, 38, 306-314.	1.4	7
86	Conversion to C2 monitoring of cyclosporine A exposure in maintenance kidney transplant recipients: results at 3 years. American Journal of Kidney Diseases, 2004, 44, 886-92.	2.1	8
87	Transcriptional regulation of the β1C integrin splice variant in human prostate adenocarcinoma. International Journal of Oncology, 2003, 23, 1601.	1.4	4
88	Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation, 2003, 75, 998-1003.	0.5	74
89	Repair of Vaginal Prolapse following Penoscrotal Flap Vaginoplasty in a Male-to-Female Transsexual. Gynecologic and Obstetric Investigation, 2002, 53, 234-236.	0.7	18
90	Bicalutamide Monotherapy versus Flutamide plus Goserelin in Prostate Cancer: Updated Results of a Multicentric Trial. European Urology, 2002, 42, 481-490.	0.9	39

#	Article	IF	CITATIONS
91	Regulation of mRNA and Protein Levels of β1 Integrin Variants in Human Prostate Carcinoma. American Journal of Pathology, 2000, 157, 1727-1734.	1.9	47
92	Bicalutamide Monotherapy Versus Flutamide Plus Goserelin in Prostate Cancer Patients: Results of an Italian Prostate Cancer Project Study. Journal of Clinical Oncology, 1999, 17, 2027-2027.	0.8	148
93	Spontaneous Rupture of an Ileal Neobladder 6 Years After Construction. Journal of Urology, 1997, 157, 1841-1841.	0.2	10